IDH2 and central nervous system cancer: Since IDH enrichment has not been previously described in dMMR gliomas, the diagnosis of PMMRDIA could be overlooked as an IDH‐mutant glioma based on IDH immunohistochemical (IHC) staining alone, unless a suspicion of dMMR existed, especially in the context of treatment‐naïve glioma.